How FDA Priority Review for Veligrotug Reshapes Viridian Therapeutics’ (VRDN) Thyroid Eye Disease Investment Story

Viridian Therapeutics recently announced that the FDA has accepted its Biologics License Application for veligrotug in thyroid eye disease under Priority Review, setting a June 30, 2026 target action date and confirming commercial preparations are underway. The company also outlined a packed 2026 pipeline calendar, with multiple phase 3 readouts for elegrobart and new IND-stage programs that could broaden its thyroid-related portfolio. Next, we examine how Priority Review for veligrotug may influence Viridian’s investment narrative and perceived strength of its thyroid eye disease franchise. Explore 29 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.What Is Viridian Therapeutics' Investment Narrative?For Viridian, the big picture an investor needs to believe in is that thyroid eye disease can support a focused, multi-asset franchise that eventually justifies today’s loss-making profile and premium sales multiple. The FDA’s Priority Review for veligrotug does not change the core story, but it sharpens the near-term catalyst map: the June 30, 2026 PDUFA date now anchors the timeline, while 2026 phase 3 readouts for subcutaneous elegrobart and early data from new thyroid programs become incremental proof points around that. At the same time, the key risks are also clearer. Viridian is still unprofitable with a history of shareholder dilution, and the valuation already embeds high expectations. The recent news mostly pulls existing catalysts forward rather than adding entirely new ones. However, one risk in particular could catch investors off guard if things do not go to plan. Despite retreating, Viridian Therapeutics' shares might still be trading above their fair value and there could be some more downside. Discover how much.Exploring Other PerspectivesVRDN 1-Year Stock Price Chart Three fair value estimates from the Simply Wall St Community range widely, from near zero to very high levels, underscoring how differently people price Viridian’s TED opportunity. You are weighing that dispersion against a story now more tightly tied to the veligrotug PDUFA decision and 2026 trial readouts, which could sharpen views on the company’s longer term earnings power.Explore 3 other fair value estimates on Viridian Therapeutics - why the stock might be worth less than half the current price!Build Your Own Viridian Therapeutics NarrativeDisagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.A great starting point for your Viridian Therapeutics research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.Our free Viridian Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Viridian Therapeutics' overall financial health at a glance.Interested In Other Possibilities?Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:These 16 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit.Uncover the next big thing with financially sound penny stocks that balance risk and reward. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.